SCD and metabolic dysfunction-associated steatotic liver disease: Recent data obtained both in mice and rats have reported the discovery of potent SCD1 inhibitors able to reduce steatosis without significant adverse events thus representing innovative and promising therapeutic compounds for NAFLD treatment [53].